Sweeney noted that recent additions to the GS expression system toolbox, the MGV (multigene vectors) and GS piggyBac transposon technology, are being used to enhance complex protein expression including bispecific antibodies. Improved vector design, host cell engineering, and novel purification and analytical methods are some of Lonza's innovative approaches. The teams are looking at ways of improving bispecific antibody heavy and light chain pairing to ensure optimal production of the desired product Sweeney revealed that these novel formats usually don't fit the standard platform process they require new solutions. 'Often with bispecific antibodies and other novel formats it is a much more complicated process requiring longer timelines and more resources,' she explained. 'With standard antibodies, there is an expectation to go from DNA to investigational new drug application (IND) in 12 months,' Sweeney commented, emphasising that clients are now coming with increasingly complex molecules expecting similar timelines. Lonza's customer base is made of companies of all sizes, including leading biopharma and small SMEs who may not have the know-how or technology to develop a manufacturing cell line and production process in-house. The Swiss CDMO uses its GS expression platform to generate the production cell line that will be used to manufacture the product. Typically, Lonza works with customers once they have selected their lead candidate(s). 'Over 20% of the molecules that are coming to us now are bispecific antibodies,' R&D Director Bernadette Sweeney told us as she presented the Lonza strategy to provide CDMO services for the growing pipeline of complex molecules.Д«ispecific antibodies are capable of binding two unique antigens simultaneously, and main applications are immunotherapy and oncology therapeutic areas. That day, the scientists behind the brand revealed how their teams work, pushing the boundaries of science and business acumen to deliver on the promise of a timely and cost-efficient commercial launch of innovative medicines. Guided by high-rank executives, we toured the facility traversing from one building to the next - R&D, microbial, bioconjugates, and the Ibex Solutions building under construction - in the same fashion most Visp workers do: pedalling a bike. It was a sunny blue-skied autumn day when Manufacturing Chemist visited Visp as part of a handful of international media invited to the exclusive open day event. The site now also contains 70 labs, R&D and scale-up facilities, and state-of-the-art multipurpose plants, totalling more than 850 cubic metre of production capacity rendered by the work of more than 3,000 staff. The century-old structures built to house Lonza's quest for calcium carbide (CaC2) applications - the core business at the time - still stand at the heart of the 900,000 sqm industrial compound. Jodern Wine Cellars by the Heida wine village in Visperterminen (Europe's highest vineyard) that remains in my memory, but the view of the founding location of the Swiss CDMO living proof of its 123 years in operation. It's not the 2-hour train journey through the jaw-dropping scenery of Lake Geneva or the dinner at St.

Visiting Visp, the manufacturing facility of Lonza in Switzerland, has been hard to forget.

Lonza bluesense